Synthetic feline facial pheromone (FFP) (Feliway; Ceva Animal Health) was assessed for the management of cats with recurrent feline idiopathic cystitis (FIC). Nine of 12 cats completed the randomised, double-blinded, placebo-controlled, crossover pilot study. They had their environment treated daily with either FFP or placebo for 2 months, after which time the treatment groups were reversed. Owners used visual analogue scales to define the severity of their cat's clinical signs and behavioural changes. Five (56%) of the owners stated that their cat's overall health was better when they were using FFP. Four (44%) of the owners noticed no difference between when using the FFP and when using the placebo. While there were no statistical differences between the two treatment groups there was a trend for the cats exposed to FFP to show fewer days with clinical signs of cystitis (FFP total, mean per cat±standard deviation, 30, 4.3±6.7; placebo 69, 9.9±19.1), a lower overall clinical score (1667, 238±476; 2009, 287±425), a reduced number of episodes of cystitis (9, 1.3±2.0; 10, 1.4±2.1) and reduced negative behavioural traits (e.g., less aggression and fear) (-128, -18.3±65.8; -73, -10.4±35.1).